Literature DB >> 18465287

Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology.

Jaber Emami1, Hamed Hamishehkar, Abdolhossien Rouholamini Najafabadi, Kambiz Gilani, Mohsen Minaiyan, Hamid Mahdavi, Hamid Mirzadeh, Amir Fakhari, Ali Nokhodchi.   

Abstract

The large surface area, good vascularization, immense capacity for solute exchange and ultra-thinness of the alveolar epithelium are unique features of the lung facilitating systemic drug delivery via pulmonary administration. The efficacy and safety of many new and existing inhaled therapies may be enhanced through advanced controlled-release systems by using polymer particles. Poly (D,L-lactic-co-glycolic acid) (PLGA) is well known by its safety in biomedical preparations which has been approved for human use by the FDA. The optimum aerodynamic particle size distribution for most inhalation aerosols has generally been recognized to be in the range of 1-5 microns. PLGA microspheres, therefore, were prepared by a developed oil-in-oil solvent evaporation method and characterized. A four-factor, three levels Box-Behnken design was used for the optimization procedure with temperature, stirring speed, PLGA and surfactant concentration as independent variables. Particle size and polydispersity of microspheres were considered as dependent variables. PLGA microparticles were prepared successfully in desired size for pulmonary delivery by solvent evaporation method. It was found that the particle size of microspheres could be easily controlled. It was also proved that response surface methodology could efficiently be applied for size characterization and optimization of PLGA microparticles for pulmonary drug delivery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18465287     DOI: 10.1080/02652040802083900

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  9 in total

1.  Nanoparticle deposition onto biofilms.

Authors:  J K Miller; R Neubig; C B Clemons; K L Kreider; J P Wilber; G W Young; A J Ditto; Y H Yun; A Milsted; H T Badawy; M J Panzner; W J Youngs; C L Cannon
Journal:  Ann Biomed Eng       Date:  2012-08-10       Impact factor: 3.934

Review 2.  Three-dimensional Printing and 3D Slicer: Powerful Tools in Understanding and Treating Structural Lung Disease.

Authors:  George Z Cheng; Raul San Jose Estepar; Erik Folch; Jorge Onieva; Sidhu Gangadharan; Adnan Majid
Journal:  Chest       Date:  2016-03-12       Impact factor: 9.410

3.  Aggregated Nanotransfersomal Dry Powder Inhalation of Itraconazole for Pulmonary Drug Delivery.

Authors:  Mehdi Hassanpour Aghdam; Saeed Ghanbarzadeh; Yousef Javadzadeh; Hamed Hamishehkar
Journal:  Adv Pharm Bull       Date:  2016-03-17

Review 4.  Lactose engineering for better performance in dry powder inhalers.

Authors:  Yahya Rahimpour; Hamed Hamishehkar
Journal:  Adv Pharm Bull       Date:  2012-08-15

5.  Understanding the Effects of Associated Factors in the Development of Microsponge-Based Drug Delivery: a Statistical Quality by Design (QbD) Approach Towards Optimization.

Authors:  Shibam Karmakar; Sourav Poddar; Jasmina Khanam
Journal:  AAPS PharmSciTech       Date:  2022-09-16       Impact factor: 4.026

Review 6.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

7.  Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy.

Authors:  Raphael Mietzner; Christian Kade; Franziska Froemel; Diana Pauly; W Daniel Stamer; Andreas Ohlmann; Joachim Wegener; Rudolf Fuchshofer; Miriam Breunig
Journal:  Pharmaceutics       Date:  2020-07-27       Impact factor: 6.321

8.  Fucoxanthin Loaded in Palm Stearin- and Cholesterol-Based Solid Lipid Nanoparticle-Microcapsules, with Improved Stability and Bioavailability In Vivo.

Authors:  Yaxin Chen; Niaoniao He; Ting Yang; Shuyun Cai; Yi Zhang; Jinjing Lin; Mingqing Huang; Weizhu Chen; Yiping Zhang; Zhuan Hong
Journal:  Mar Drugs       Date:  2022-03-29       Impact factor: 6.085

9.  Celecoxib Microparticles for Inhalation in COVID-19-Related Acute Respiratory Distress Syndrome.

Authors:  Monica-Carolina Villa-Hermosilla; Sofia Negro; Emilia Barcia; Carolina Hurtado; Consuelo Montejo; Mario Alonso; Ana Fernandez-Carballido
Journal:  Pharmaceutics       Date:  2022-06-30       Impact factor: 6.525

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.